



EOS imaging's Micro Dose feature highlighted at EPOS 2015

EPOS data presentations and a new installation at Colorado Children's Hospital reinforce EOS leadership in low dose pediatric imaging

Paris, April 15, 2015 - EOS imaging (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announced that its new Micro Dose option is being highlighted at the European Pediatric Orthopedic Society 34th Annual Meeting, April 15-18 in Marseille, France.

Two of the four podium communications related with EOS benefits, will present hospital's findings confirming that Micro Dose affords a drastic reduction in radiation exposure, and as such, should be used for follow-up imaging in adolescent patients with idiopathic scoliosis.

Concurrent with the Company's EPOS presence is the announcement that Children's Hospital Colorado has installed an EOS system, marking the first EOS installation in the state of Colorado. U.S. News & World Report ranks Children's Hospital Colorado seventh in the nation in pediatric orthopedics. This installation further cements EOS' leadership position in pediatric imaging in the U.S, and demonstrates the continued groundswell of EOS adoption in the country,

Dr. Brice Ilharreborde, pediatric orthopaedist at Robert Debré hospital in Paris, one of the two institutions presenting Micro Dose results at EPOS, said, *"EOS' Micro Dose feature affords surgeons and clinicians an outstanding tool to chart the safest course of treatment for their patients. The research our team is presenting at EPOS quantifies this reduction in exposure – a more than five-fold reduction – as compared to already low-dose standard EOS images. This reduction in exposure is critical for pediatric patients in need of long-term treatment monitoring and follow-up imaging, such as those with scoliosis."*

The research presented by the Robert Debré hospital team will be published in the *European Spine Journal*.

Micro Dose enables a further drastic step towards the ALARA (As Low As Reasonably Available) principle by bringing pediatric spine follow up exams at a dose level equivalent to a week of natural background radiation on Earth.

Marie Meynadier, CEO of EOS imaging, said, *"Reducing radiation exposure has been at the forefront of EOS imaging technology since its inception. The data our leading users are providing about Micro Dose at EPOS, in combination with a new installation at another leading pediatric hospital in the U.S., are strong confirmations that EOS imaging is becoming the gold standard in safe and responsible pediatric imaging in the U.S. and worldwide."*

The EOS® system provides full-body stereo-radiographic images of patients in functional positions, in both 2D and 3D. EOS exams require a radiation dose 50% to 85% less than Digital Radiology and 95% less than basic CT scans.

For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit <http://www.eos-imaging.com/>.

EOS imaging has been chosen to be included in the new EnterNext® PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI



Next press release: April 20 (2014 financial results and 2015 first quarter revenue)

**About EOS imaging:**

EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system based on technology that enabled George Charpak to win the Nobel Prize for Physics, as well as associated solutions. The Company is authorized to market in 47 countries, including the United States (FDA), Japan and the European Union (EU). As of December 31, 2014 the Group posted 2014 consolidated revenue of €20.1 million and employed 107 people including an R&D team of 39 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada) and Frankfurt (Germany), and offices in Singapore.

Contacts:**Anne Renevot**

CFO

Ph: +33 (0)1 55 25 61 24

investors@eos-imaging.com**NewCap**

Financial communication and investor relations

Antoine Denry/ Pierre Laurent

Ph: +33 (0)1 44 71 94 91

eosimaging@newcap.fr**The Ruth Group (US)**

Press relations / Calvin Allen

Ph: 646-536-7002

callen@theruthgroup.com